EP1082122A1 - Isoflavonoides utiles dans le traitement et la prevention de maux de tete du type migraine - Google Patents

Isoflavonoides utiles dans le traitement et la prevention de maux de tete du type migraine

Info

Publication number
EP1082122A1
EP1082122A1 EP99925828A EP99925828A EP1082122A1 EP 1082122 A1 EP1082122 A1 EP 1082122A1 EP 99925828 A EP99925828 A EP 99925828A EP 99925828 A EP99925828 A EP 99925828A EP 1082122 A1 EP1082122 A1 EP 1082122A1
Authority
EP
European Patent Office
Prior art keywords
composition
isoflavonoid
isoflavonoids
dietary product
migraine headaches
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP99925828A
Other languages
German (de)
English (en)
Other versions
EP1082122A4 (fr
Inventor
Sherwood L. Gorbach
Barry R. Goldin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of EP1082122A1 publication Critical patent/EP1082122A1/fr
Publication of EP1082122A4 publication Critical patent/EP1082122A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 

Definitions

  • the present invention relates to therapies for the prevention and treatment of migraine headaches and menstrual-related headaches and the symptoms associated with these headaches, particularly in women.
  • Migraine headaches are characterized by some (but not necessarily all) of the following symptoms: unilateral onset of headache; moderate to severe throbbing or pulsating head pain; photophobia (light sensitivity); premonitory aura of visual changes (blurry vision and/or flashing lights); speech difficulties; and hemiparesis (weakness or paralysis on one side). Approximately 20% of individuals experiencing a migraine headache report symptoms for a duration of four to six hours and 80% report a duration of six hours to more than twenty-four hours. In the United States between 17 and 19% of women have experienced symptoms of migraine headaches or menstrual-related headaches.
  • migraine headaches In women, about 60% of migraine headaches occur at plus or minus a two-day interval from onset of menstruation. The high frequency of migraine at menstruation is believed to result from the rapid decrease of estrogens in the blood at this time in the menstrual cycle.
  • migraine headaches are less common than in Western countries.
  • the incidence of migraine headaches among Japanese women is 40% lower than the incidence among American women.
  • the incidence of migraine headaches among elderly Chinese women is approximately 50% lower than that among age-matched American women.
  • Blood levels and urinary excretion of isoflavonoids have been studied in different population groups eating a regular diet containing either high or low amounts of isoflavonoids.
  • Japanese women who consumed soy products on a regular basis excreted 12 to 64 times more daidzein and 41 to 59 times more equol than American or Finnish women.
  • the invention features the use of purified isoflavonoids, which are constituents of soy beans and other plants such as clover, to effectively treat and prevent symptoms of headaches, in particular migraine headaches, that are caused by reduced or altered levels of endogenous estrogen. Migraine-like headaches in men are also treated with purified isoflavonoids according to the invention. Without being bound by any theory, it is believed that the isoflavonoids bind to estrogen receptors and activate cellular signal induction, and thus exert an estrogenic response. These compounds are safe and cause no significant side-effects.
  • Purified isoflavonoids which may be administered according to the invention include genistein, daidzein, biochanin A, formononetin, O-desmethylangolensin, glycitein, equol and dihydrodaidzein and their conjugates; these may be administered alone or in combination.
  • the invention provides a method for treating or preventing symptoms of migraine headache by administering (preferably orally) to the person a composition containing one or more purified isoflavonoids selected from the group consisting of genistein, daidzein, biochanin A, formononetin, O-desmethylangolensin, glycitein, equol, and dihydrodaidzein and their conjugates in an amount sufficient to produce a transient isoflavonoid concentration in the bloodstream of the person of at least 10 ng/ml.
  • the composition is administered orally, providing a dosage of at least 20 mg of total isoflavonoid per serving.
  • the orally-administrable composition can be a non-naturally occurring dietary product such as a confectionary bar, cereal, biscuit, or beverage.
  • the composition can take the form of a medicament such as a pill, capsule, tablet, powder, or syrup, in which the total isoflavonoid is present in at least an amount of 20 mg per unit dose.
  • the dietary product or medicament is orally consumed by the person once, twice, or three times per day, to provide a daily oral isoflavonoid dose of between 20 and 300 mg.
  • the oral ingestion of the composition is sufficient to produce in the bloodstream of the person a transient concentration of total isoflavonoid of at least 10 ng/ml.
  • purified isoflavonoid is meant an isoflavonoid in more concentrated form than occurs in plants.
  • each isoflavonoid administered according to the invention is at least 3%, more preferably at least 30% pure by weight.
  • the isoflavonoid-containing composition can be included in a transdermal delivery system or patch.
  • Isoflavonoids are naturally occurring compounds, found primarily in soy beans. These compounds are also found in high concentrations in red clover and in lower amounts in many other types of plants.
  • An isoflavonoid- containing fraction (containing purified isoflavonoids) useful in the invention can be extracted from a soy or plant product using known methods. It is preferred that the isoflavonoids be extracted and concentrated from soy beans or soy powder, but other plants such as clover can be used.
  • An isoflavonoid- containing fraction can be extracted from a soy or plant product in concentrations between 3 and 30% isoflavonoids. Isoflavonoids are also available commercially in substantially pure form.
  • the concentrated isoflavonoid is preferably administered either in pill, capsule, tablet, powder, or syrup form, or as an additive to a flavored drink, or as a component of a confectionary bar, biscuit, or cereal containing suitable flavoring to constitute a palatable product.
  • An isoflavonoid-containing transdermal patch can be of conventional form, e.g., that used to deliver sustained doses of nicotine or estrogen.
  • Isoflavonoids have similar chemical properties to estrogens, e.g., they are poorly soluble in water but are readily soluble in alcohols and other organic solvents.
  • the isoflavonoid is mixed in a base with ingredients such as alcohol, mineral oil, glyceryl monostearate, an ether complex of fatty acids, acetyl alcohol, lanolin, propylene glycol, stearyl alcohol, and sodium lauryl sulfate.
  • concentration of isoflavonoid is 1 to 40 mg per gram of the base, more preferably 10 to 25 mg per gram of base.
  • Other embodiments are within the claims.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne un procédé de traitement ou de prévention, chez une personne, d'un ou de plusieurs symptômes de céphalées du type migraine, ce procédé consistant à administrer à cette personne, oralement ou au moyen d'un système ou timbre transdermique, une composition comprenant un ou plusieurs isoflavonoïdes purifiés, choisis dans le groupe constitué par génistéine, daïdzéine, biochanine A, formononétine, O-desméthylangolensine, glycitéine, équol et dihydrodaïdzéine, et les conjugués de ceux-ci.
EP99925828A 1998-05-27 1999-05-25 Isoflavonoides utiles dans le traitement et la prevention de maux de tete du type migraine Withdrawn EP1082122A4 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US85480 1993-06-21
US8548098A 1998-05-27 1998-05-27
PCT/US1999/011532 WO1999061028A1 (fr) 1998-05-27 1999-05-25 Isoflavonoides utiles dans le traitement et la prevention de maux de tete du type migraine

Publications (2)

Publication Number Publication Date
EP1082122A1 true EP1082122A1 (fr) 2001-03-14
EP1082122A4 EP1082122A4 (fr) 2003-04-09

Family

ID=22191888

Family Applications (1)

Application Number Title Priority Date Filing Date
EP99925828A Withdrawn EP1082122A4 (fr) 1998-05-27 1999-05-25 Isoflavonoides utiles dans le traitement et la prevention de maux de tete du type migraine

Country Status (4)

Country Link
EP (1) EP1082122A4 (fr)
AU (1) AU4204099A (fr)
CA (1) CA2333556A1 (fr)
WO (1) WO1999061028A1 (fr)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1132084A1 (fr) * 2000-03-06 2001-09-12 Docteur Nature Srl Dispositif d'administration transdermique destiné à la libération lente de phytoestrogènes provenant de soja
ATE343415T1 (de) 2001-06-29 2006-11-15 Ab Science Die verwendung von c-kit hemmer zur behandlung von entzündlichen darmerkrankungen
JP2005500041A (ja) 2001-06-29 2005-01-06 アブ サイエンス 強力で選択的かつ非毒性のｃ−ｋｉｔ阻害剤
DK1401413T3 (da) 2001-06-29 2007-03-26 Ab Science Anvendelse af tyrosinkinaseinhibitorer til behandling af allergiske sygdomme
JP2004537537A (ja) 2001-06-29 2004-12-16 アブ サイエンス 炎症性疾患を治療するためのチロシンキナーゼ阻害剤の使用法
DK1478380T3 (da) * 2002-02-27 2006-11-27 Ab Science Anvendelse af tyrosinkinase-inhibitorer til behandling af CNS-lidelser
WO2004039327A2 (fr) 2002-10-29 2004-05-13 Colorado State University Research Foundation Utilisation d'equol dans le traitement de maladies d'origine androgenique
US8668914B2 (en) 2002-07-24 2014-03-11 Brigham Young University Use of equol for treating skin diseases
WO2004009035A2 (fr) 2002-07-24 2004-01-29 Children's Hospital Medical Center Compositions et produits contenant de l'equol enantiomere, et procedes de fabrication
US8580846B2 (en) 2002-10-29 2013-11-12 Brigham Young University Use of equol for ameliorating or preventing neuropsychiatric and neurodegenerative diseases or disorders
NZ526098A (en) * 2003-05-23 2005-10-28 Enzo Nutraceuticals Ltd Use of a plant extract containing flavonoids rich in proanthocyanidins for the prevention or treatment of migraine
JP2008507525A (ja) * 2004-07-23 2008-03-13 ザ プロクター アンド ギャンブル カンパニー 基材ベースのスキンケアデバイス

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998008503A1 (fr) * 1996-08-30 1998-03-05 Novogen Research Pty. Ltd. Procedes therapeutiques et compositions integrant des isoflavones
EP0906761A2 (fr) * 1997-10-02 1999-04-07 Archer-Daniels-Midland Company Procédé de préparation et d'utilisation de produits phytochimiques

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5204369A (en) * 1991-07-01 1993-04-20 The Endowment For Research In Human Biology Method for the inhibition of aldh-i useful in the treatment of alcohol dependence or alcohol abuse
US5807586A (en) * 1996-07-30 1998-09-15 Energetics, Inc. Method of dietary supplementation

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998008503A1 (fr) * 1996-08-30 1998-03-05 Novogen Research Pty. Ltd. Procedes therapeutiques et compositions integrant des isoflavones
EP0906761A2 (fr) * 1997-10-02 1999-04-07 Archer-Daniels-Midland Company Procédé de préparation et d'utilisation de produits phytochimiques

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
HIRAKURA K ET AL: "Phenolic glucosides from the root of Pueraria lobata" PHYTOCHEMISTRY, PERGAMON PRESS, GB, vol. 46, no. 5, November 1997 (1997-11), pages 921-928, XP004293503 ISSN: 0031-9422 *
KITAZONO TAKANARI ET AL: "Role of tyrosine kinase in serotonin-induced constriction of the basilar artery in vivo." STROKE, vol. 29, no. 2, February 1998 (1998-02), pages 494-498, XP002229783 ISSN: 0039-2499 *
See also references of WO9961028A1 *

Also Published As

Publication number Publication date
AU4204099A (en) 1999-12-13
CA2333556A1 (fr) 1999-12-02
EP1082122A4 (fr) 2003-04-09
WO1999061028A1 (fr) 1999-12-02

Similar Documents

Publication Publication Date Title
US5498631A (en) Method for treatment of menopausal and premenstrual symptoms
AU724813B2 (en) Isoflavonoids for treatment and prevention of Alzheimer dementia and reduced cognitive functions
EP0656786B1 (fr) Utilisation d'extraits des phyto-estrogenes d'isoflavones a partir de soja ou de trefle
CA2287965C (fr) Traitement ou prevention des symptomes menopausiques et de l'osteoporose
US6060070A (en) Isoflavonoids for treatment and prevention of aging skin and wrinkles
US6900240B2 (en) Method of preparing and using compositions extracted from vegetable matter for the treatment of cancer
US4886665A (en) Compositions of oats and nettle extracts to be used as a food additive or pharmaceutical preparation in human health care
US6083526A (en) Use of isoflavonoids in the treatment or prevention of postpartum depression
WO1999061028A1 (fr) Isoflavonoides utiles dans le traitement et la prevention de maux de tete du type migraine
CN100366628C (zh) 槐角黄酮有效部位、生产方法及其应用
US20070059393A1 (en) Composition for inhibition or prevention of bone density
WO2007042745A1 (fr) Suppresseur d'appetit a base de chocolat
JPH09255570A (ja) 血中脂質濃度を低減させる薬剤及び可食性組成物
KR20100129571A (ko) 정자수 증가와 환경호르몬 예방효과를 갖는 성기능 개선 조성물 및 이를 함유하는 성기능 개선용 식품
JPH08231533A (ja) 新規フラボノイド配糖体およびフラボノイド配糖体を含む骨粗鬆症治療剤ならびに可食性組成物
Montanari et al. Health promoting phytochemicals in citrus fruit and juice products
JP2004210675A (ja) 骨量改善組成物
JP2004196751A (ja) 更年期症状改善組成物
WO2001087315A1 (fr) Traitement ou prevention d'affection metabolique osseuse
AU777632B2 (en) Health supplements containing isoflavones
US20080161385A1 (en) Composition Inhibiting Sex Hormone-Binding Globulin
AU7017198A (en) Treatment or prevention of menopausal symptoms and osteoporosis

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20001219

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

A4 Supplementary search report drawn up and despatched

Effective date: 20030224

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20031203